Newsfeeds - Spark Newswire

2 minute read

Medical Marijuana Milestone In The UK: Celadon Pharmaceuticals Becomes First Company With License To Sell In Britain

Today, 3:42 AM

Celadon Pharmaceuticals has become the first UK-based medical cannabis manufacturer to be granted a Home Office license to sell its products in the UK.

JAZZ

3 minute read

Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries

By Nina Zdinjak

Today, 3:42 AM

Last week the US economy got clobbered by the biggest banking collapse since 2008 when the parent of Silicon Valley Bank, SVB Financial Group (NASDAQ: SIVB) failed to raise enough capital to continue.

AAWH

4 minute read

Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying

By Nina Zdinjak

Today, 3:42 AM

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) recently published collected data on CBD safety, placing the information under its Yellow Card alert system, which lists various adverse reactions to drugs in general. In the report, the agency notes that as many as 10 people have died from CBD and more than 870 experienced adverse reactions.

ACB

1 minute read

HC Wainwright & Co. Reiterates Buy on Jazz Pharmaceuticals, Maintains $204 Price Target

By Benzinga Newsdesk

Today, 3:42 AM

HC Wainwright & Co. analyst Oren Livnat reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $204 price target.

JAZZ

3 minute read

Why Cannabis Is Recession-Resistant & Turning Challenges Into Opportunities, Industry Expert Explains

By Nina Zdinjak

Today, 3:42 AM

It is safe to say that the cannabis industry would not have progressed as much as it has if it were not for the people who believed in it. Cannabis advocates, lobbyists, growers, operators, consumers and researchers have consistently played a crucial role in the space. Nevertheless, without capital, the industry wouldn’t have advanced to where it is today.

AAWH

1 minute read

Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $205

By Benzinga Newsdesk

Today, 3:42 AM

Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and lowers the price target from $210 to $205.

JAZZ

2 minute read

Jazz Pharmaceuticals Sees FY23 EPS $16.90-$17.85 Vs $18 Est.; FY23 Revenue $3.675B-$3.875B Vs $3.76B Est.

By Happy Mohamed

Today, 3:42 AM

2023 Financial Guidance Jazz Pharmaceuticals' full year 2023 financial guidance is as follows: (In

JAZZ

1 minute read

Jazz Pharmaceuticals Q4 EPS $(0.07) Misses $0.32 Estimate, Sales $972.12M Miss $975.59M Estimate

By Happy Mohamed

Today, 3:42 AM

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.32 by 121.88 percent. This is a 101.66 percent decrease over earnings of $4.21 per share

JAZZ

11 minute read

Earnings

Earnings Scheduled For March 1, 2023

By Benzinga Insights

Today, 3:42 AM

Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.

AAN

2 minute read

Cannabis-Based Medicine As A Potential Treatment For Psychosis, An Oxford University Study Says

By Joana Scopel

Today, 3:42 AM

The Department of Psychiatry at the University of Oxford will conduct an international study to investigate whether cannabis-based medicine can treat psychosis.

JAZZ